Holistic Life: WHO Conflicts of Interest 1

#EXIT

PANDEMIC

TET RAY

INTERNATIONAL

HEALTH REGULATIONS

“WHO never publishes individualDOIs [declaration of interest], except after consultation with the Office of the Director-General.”

https://www.bmj.com/bmj/section-pdf/186584?path=/bmj/340/7759/Feature.full.pdf

“The WHO has fallen victim to neoliberal globalisation and to the economic interests of powerful nations and the transnational corporations

Former WHO employee

I“f it proves to be the case that authors of WHO guidance which promoted the use of certain drugs were being paid at the same time by the makers of those drugs for other work they were doing for these companies that is reprehensible and should be condemned in the strongest possible terms.”

Professor Chris Del Mar Professor of Public Health at Bond University

WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) member and Cochrane reviewer

https://www.bmj.com/bmj/section-pdf/186584?path=/bmj/340/7759/Feature.full.pdf

WHO - Corruption and Conflicts of Interest

Was it appropriate for WHO to take advice from experts who had declarable financial and research ties with pharmaceutical companies producing antivirals and influenza vaccines?

Why was key WHO guidance authored by an influenza expert who had received payment for other work from Roche, manufacturers of oseltamivir, and GlaxoSmithKline, manufacturers of zanamivir?

https://www.bmj.com/bmj/section-pdf/186584?path=/bmj/340/7759/Feature.full.pdf

WHO Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics 2004

Prof. Karl Nicholson, Member of The European Scientific Working Group on Influenza (ESWI), Prof. Frederick Hayden, University of Virginia, Dr. Arnold Monto, University of Michegan

Prof Nicholson is on the Roche pharmaceutical Company Payroll. He conducted a randomised controlled trial on oseltamivir (Tamiflu) supported by Roche and also received travel sponsorship and honorariums from GlaxoSmithKline and Roche for consultancy work and speaking at international respiratory and infectious diseases symposiums. Also received consultancy fees by Wyeth, Chiron, and Berna Biotech

Prof Hayden paid by Roche for lectures and consultancy work for the company at the time the guidance was produced and published, also received payments from GlaxoSmithKline for consultancy and lecturing until 2002. He also served on WHO Strategic Advisory Committee on Immunization, Vaccines and Biologicals (SAGE) and Board of Wellcome Trust

Prof Monto received honorariums, consultancy fees, and research support from GSK, Novartis, Roche, Baxter, Sanofi, MedImmune, and consultancy fees and research (GlaxoSmithKline, $3000 speakers fees in 2009) and also research funding from ViroPharma.

Sponsors

https://fulldisklosure.wordpress.com/2009/12/10/mega-corruption-scandal-at-the-who/ https://ch.linkedin.com/in/daniel-lavanchy-04349314

https://www.bmj.com/content/bmj/340/7759/Feature.full.pdf http://vaccineresistancemovement.org/?p=4610

https://eswi.org/home/about-eswi/resources/

Prof Albert Osterhaus

trustWHO

Albert Osterhaus: Global Elitist Hack

	WHO Strategic Advisory Committee on Immunization, Vaccines and Biologicals (SAGE)
	Director of the WHO Collaborating Centre for Arboviruses and Haemorrhagic Fever Reference and Research, Rotterdam (since 1995)


Co-Founder and Chairman of the Scientific Advisory Board	9.8% share
Vaccine Development

Chair European Scientific Working Group on Influenza (ESWI)


Board Member
	Vaccine development and Protein production


Prof of Virology
			European Commission

Partner

Chief Scientific Officer

Vaccine Development

Scientific Advisory Board member


		International One Health Coalition
Member

Partners

Prof Albert Osterhaus

Publication Funding

Scientific Advisory Board member

Vaccine Development

Scientific Advisory Board

Zoonoses vaccines

Chair/Initiator

Ad Hoc Policy advisory SAGE Working Group on influenza A (H1N1) vaccines (April 2009 to April 2010)

SAGE Members	SAGE Experts	Institution	WHO Secretariat
David Salisbury, Chair Jon Abramson Supamit Chunsuttiwat	Nancy Cox Neil Ferguson Teeranart Jivapaisarnpong Paul-Henri Lambert Johannes Loewer Karen Midthun Phillip Minor Albert Osterhaus Stefania Salmaso Peter Smith	- Centers for Disease Control and Prevention, USA - Imperial College, UK - Ministry of Public Health, Thailand - Centre Médical Universitaire, Switzerland - Paul-Ehrlich Institut, Germany - WHO Global Advisory Committee on vaccine Safety, Center for Biologics Evaluation and Research, USA - WHO Expert Committee on Biological Standardization, National Institute for Biological Standards and Control, UK - Erasmus MC, Netherlands - WHO Global Advisory Committee on vaccine Safety, Istituto Superiore di Sanità, Italy - WHO Global Advisory Committee on vaccine Safety, London School of Hygiene and Tropical Medicine, UK	Marie-Paule Kieny Philippe Duclos

https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/working-groups/influenza-a-(h1n1)-vaccines-(april-2009-to-april-2010)

The European Scientific Working Group on Influenza

(FluMist Quadrivalent Vaccine Manufacturer)

(Zanamivir, H1N1 inhibitor)
(H1N1 Fluarix Quadrivalent Vaccine)

(Oseltamivir, H1N1 inhibitor)
(H1N1 Afluria Quadrivalent Vaccine)

(H1N1 Fluzone Quadrivalent Manufacturer)

Novartis (Influenza A (H1N1) 2009 Monovalent Vaccine Manufacturer)

Hofmann-La Roche

(H1N1 Vaccine Distributor)

(H1N1 Vaccine Manufacturer) MedImmune (H5N1 FluMist Quadrivalent Vaccine)

Baxter Vaccines

https://eswi.org/site/eswi/financial-supporters

https://www.fda.gov/media/123144/download

Albert Osterhaus: Global Elitist Hack

Albert Osterhaus: Role in the Neuraminidase Conspiracy

Journal Title

Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections

Authors

Journal and Date

September 25, 1997. N. Engl. J. Med 1997; 337:874-880

Funders

Glaxo Wellcome

Neuraminidase Inhibitors for Treatment of Influenza A and B Infections

F.G. Hayden, A.D.M.E. Osterhaus, J,J. Treanor, D.M. Fleming, Fred Y. Aoki, K.G. Nicholson, A,M. Bohnen, H.M. Hirst, O. Keene, and K. Wightman, the GG167 Influenza Study Group

December 17, 1999. Morbidity and Mortality Weekly Report (CDC) 48(RR14);1-9

CDC

Efficacy and safety of in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group

oseltamivir

Andrea G. Winquist, Keiji Fukuda, Carolyn B. Bridges, Nancy J. Cox.

May 27, 2000. Lancet, 2000;355(9218):1845- 50

Oseltamivir

Influenza A(H1N1) page16image513377504 Resistant Viruses in the Netherlands During the Winter 2007/2008

K G Nicholson 1 , F Y Aoki, A D Osterhaus, S Trottier, O Carewicz, C H Mercier, A Rode, N Kinnersley, P Ward

F. Dijkstra, M. Jonges, R, van Beek, G.A Donker, F.G Schellevis, M. Koopmans, M.A.B van der Sande, A.D.M.E Osterhaus, C.A.B Boucher, G,F Rimmelzwaan, and A. Meijer

Dec 23, 2011. Open Virol J. 2011; 5: 154–162.

Oseltamivir

-resistant pandemic A(H1N1) 2009 influenza viruses detected through

enhanced surveillance in the Netherlands, 2009–2010

Influenza Virus Resistance to Antiviral Therapy

Global Assessment of Resistance to Neuraminidase Inhibitors, 2008–2011: The Influenza Resistance Information Study (IRIS)

A. Meijer, Albert Osterhaus, Marion Koopmans et.al

Erhard van der Vries 1 , Martin Schutten, Pieter Fraaij, Charles Boucher, Albert Osterhaus

R. J. Whitley, C. A. Boucher, B. Lina, J. S. Nguyen- Van-Tam, Albert Osterhaus, M. Schutten, Arnold S. Monto

Antiviral Research, Volume 92, Issue 1, October 2011, Pages 81-89

2013. Advances in Pharmacology Volume 67, 2013, Pages 217-246

1 May 2013. Clinical Infectious Diseases, Volume 56, Issue 9,, Pages 1197–1205,

Roche, GlaxoSmithKline

Albert Osterhaus: Patents and Conflicts of Interest

Patent Description	Application Number	Filed Date	Inventors
A human monoclonal antibody blocking SARS-CoV-2 infection	2003632.3	March 12, 2020	Chunyan Wang, Wentao Li, Dubravka Drabek, Nisreen M. A. Okba, Rien van Haperen, Albert D. M. E. Osterhaus, Frank J. M. van Kuppeveld, Bart L. Haagmans, Frank Grosveld & Berend-Jan Bosch
Human Betacoronavirus Lineage C and Identification of N-Terminal Dipeptidyl Peptidase As Its Virus Receptor	17/027,295	September 21, 2020	Bartholomeus Leonardus Haagmans, Theodorus Marinus Bestebroer, Sander van Boheemen, Ronaldus Adrianus Maria Fouchier, Albertus Dominicus Marcellinus Erasmus Osterhaus, Ali Moh Zaki, Victor Stalin Raj, Berend Jan Bosch
Virus causing respiratory tract illness in susceptible mammals	11162148	December 30, 2019	Jan Cornelius De Jong, Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus D. M. E. Osterhaus, Jan Groen
Influenza vaccine	10485863	July 25, 2011	Albertus D. M. E. Osterhaus, Bror Morein, Karin Lövgren Bengtsson
Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus	20100297730	December 22, 2008	Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Aurelia Haller, Roderick Tang
Mammalian positive-sense single stranded RNA virus (SARS) within the group of coronaviruses and components thereof.	10/552,755	Apr 8, 2004	Bartholomeus Haagmans, Thijs Kuiken, Ronaldus Fouchier, Albertus Dominicus Osterhaus

https://www.gatesfoundation.org/about/committed-grants/2018/03/opp1189447

“Their Man on the Inside”

Tedros Adhanom Ghebreyesus: “Prostituting himself”

Director-General

Chair (2009 to 2011)

Board Member

The High Level Taskforce on Innovative International Financing for Health Systems

M e m b e r

Chair, Coordinating Board

Board Member

Institute for Health Metrics and Evaluation

Member

Harvard School of Public Health

Associate

Advisory Board

Agenda Contributor

Fig. Bill Gates and Tedros Adhanom Gherbreyesus

“I met with the Bill and Melinda Gates Foundation and Emmanuel Macron, French president to get funding totalling 7.4 billion euros in pledges from the Global Fund to research and for the distribution of vaccines against COVID-19”
Dr Tedros Ghebreyesus, WHO Director-General (6 May 2020)

The Tigray People’s Liberation Front (TPLF) and Dr Tedros Adhanom Ghebreyesus

Table: The United States has classified the TPFL as a Tier III terrorist organization.

* listed in the U.S. Homeland Security Global Terrorism Database

Positions Held:

Executive Member of the Tigray People's Liberation Front Ethiopian Minister of Foreign Affairs
Ethiopian Minister of Federal Ministry of Health

Dr Tedros Adhanom Ghebreyesus

https://vaccineimpact.com/2020/is-w-h-o-director-tedros-a-terrorist-global-ties-to-bill-gates-clinton-foundation-dr-fauci-china-and-genocide/ https://www.uscis.gov/sites/default/files/USCIS/Laws/TRIG/2014_Implementation_of_New_Discretionary_Exemption_for_Activities_or_Associations_Relating_to_TPLF.pdf

Tedros Gheybreyesus, was leader of Ethiopia’s brutal minority party, the Tigray People’s Liberation Front, a wing of the ruling Marxist-rooted Ethiopian People’sRevolutionary Democratic Front (EPRDF). The TPLF is designated and qualifies as a Tier III terrorist organization under INA section 212(a)(3)(B)(vi)(III) (United States Department of Homeland Security) on the basis of its violent activities before it became part of the ruling coalition and the government of Ethiopia in May 1991.

Birhanu Jula, a general with the Ethiopian army, recently (2020) accused Ghebreyesus of helping the rebel group Tigray People’s Liberation Front (TPLF) procure weapons.

In a complaint filed at the International Criminal Court in The Hague, Nobel Prize nominee David Steinman has accused Ghebreyesus of supporting genocide in Ethiopia which involved the murder, detention and torture of many indigenous people, belonging to the Amhara, Konso, Oromo and Somali tribes.

https://neonnettle.com/news/11077-who-chief-was-leader-of-group-designated-terrorists-by-u-s-government

https://www.theblaze.com/news/tedros-accused-of-covering-up-epidemics-in-2017

WHO’s Dr Maria D. Van Kerkhove: “Globalist Hack and Elitist Puppet”

Prof Neil Ferguson

Senior Research Fellow Honorary Lecturer

Post-Doctoral Fellow

PhD Degree

Masters Degree

Dr Maria D. Van Kerkhove

COVID-19 Technical Lead of the World Health Organization (WHO)

Undergraduate Degree

https://covid19responsefund.org/en/supporters/

The Corporatization of the WHO: A Question of Independence?

International Health Regulations Committee (IHR)

Conflicts of Interest

International Health Regulations (IHR) Committee

* Acting Chair of the FDA's Vaccines and Related Biological Products Advisory Committee

* Scientific Advisory Group for Emergencies (SAGE)(UK)
* Head of International Health Regulations (IHR) (2005) Emergency Steering Committee
* Funding from Bill and Melinda Gates Foundation, Wellcome Trust, CEPI, GAVI,

* Consultant for Roche, Novartis, Baxter and GSK Biologicals

* Funding from Sanofi,Janssen, Thermo-Fischer Scientific

* Consultant for GSK, Novartis, Roche, Baxter and Sanofi

* His research unit funding from Sanofi Pasteur for influenza vaccine trial conducted in 2007- 2008

Prof Neil M. Ferguson Imperial College, London

Dr Nancy J. Cox

* Past Director of the Influenza Division at the Centers for Disease Control and Prevention (CDC)

Prof Arnold Monto, University of Michigan

* Director, WHO Collaborating Centre for Reference and Research on Influenza
* WHO Essential Reference Laboratory of GISRS

* Member UK Scientific Advisory Group for Emergencies (SAGE)

* Director of CDC’s World Health Organization (WHO) Collaborating Center for Surveillance, Epidemiology and Control of Influenza

* Deputy Director Public Health England
* Member of International Health Regulations

(IHR) (2005) Steering Committee

* UK Health Protection Agency Centre for Infection (Zambon Lab) funding sources, Sanofi, Novartis, CSL, Baxter and GSK.

* Publications funding: Bill and Melinda Gates Foundation Wellcome Trust

* Support of Jeremy J. Farrar (Wellcome Trust) and World Health Organization

Masato Tashiro

* Co-Director of the NIHR Respiratory Health Protection Unit with Imperial College London

Prof Maria Zambon Deputy Director Public Health England

Prof Neil Ferguson: Covid Modeller and Major Conflicts of Interest

Consultant, World Bank – Pandemic threats (before 2020)

Advisor to Chief Medical Officer UK

Scientific Advisory Group for Emergencies (SAGE)

Scientific Pandemic Influenza Group on Modelling (SPI-M)

New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG)

Prof Neil Ferguson, Principal “Crook”

Founder and Director
MRC Centre for Global Infectious Disease Analysis

Vaccine Impact Modelling Consortium

Director, WHO Collaborating Centre for Infectious Disease Modelling

WHO – Multiple disease Team Member

Scientific Advisor
International Health Regulations (2005)

Funding

Director
Health Protection Research Unit for Modelling Methodology

Director Abdul-Latif Jameel Institute of

Disease and Emergency Analytics

Order of the British Empire (OBE), 2002

$400 million (2018)

$8.4 million (2018)

$11 million

$206 million

$864 million

Consultant

Global Preparedness Monitoring Board

Director of PepsiCo (2005). Advisor NIH

Bilderberger (1983)

Wellcome Trust

https://silview.media/2020/09/09/exclusive-final-evidence-covid-19-is-a-a-simex-planned-simulation-exercise-by-who-and-world-bank/

Wellcome Trust Ltd invested in Corporate Elite

Williams Burns
CEO of Roche Holdings, is one of the Board of Governors of Wellcome Trust

Elhadj As Sy

Co-chair of the WHO/World Bank Global Pandemic Preparedness Monitoring Board, and Board of Governors of Wellcome Trust

https://www.thejustin.org/post/money-can-t-buy-justice

Dr Jeremy Farrar: ‘Globalist Elitist Hack’

WHO Chief Scientist

Advisor, WHO Director-General

Chair, WHO R&D Blueprint Advisory Group

UK Scientific Advisory Group for Emergencies (SAGE)

Agenda Contributor

WEF Meeting (2016-2023)

Chair of GRL Board

Participant (2023)

Jeremy Farrar

WHO Chief Scientist

COVID-19 National Core Studies (NCS) programme

Members of the Oversight Committee

Royal Fellow

Member, Global Preparedness Monitoring Board

Member, Principles Group and Facilitation Council

Chair and Founding Member


2021 Monkeypox Tabletop Exercise
Participant (2021)
Partners

OSCHR (Office for Strategic Coordination of Health Research)

Member Temasek Board and International Panel

Strategic Coherence of ODA-funded Research

Member of Board

US Fellow

Advisory and Editorial Board

Founding partner and Board Member

Member

Member of Council

Former Director

Geneva Science and Diplomacy Anticipator

Board of Directors

German

Member Global Health Advisory Board

Fellow

Vice Chair

Member, Research Funding Advisory Board

Member of Board

Jeremy Farrar: Participant in 2021 Munich Security Conference – Global Elitist Hack

2021 Monkeypox Tabletop Exercise

Participant (2021)

https://drive.google.com/file/d/1ounVsrM8K042r5dYBZl2uVZ-KJl2hQXv/view

A Picture paints a ‘Thousand Words’

Co-Conspirator

Genocidal Maniac

Jeremy Farrar Director Wellcome Trust

Wellcome Trust Ltd invested in Corporate Elite

The major funder of health research stands to gain financially from the pandemic, raising questions about transparency and accountability

The BMJ finds, Wellcome itself holds investments in companies producing these same treatments. Financial disclosures from late 2020 show that Wellcome has a £275m (€318m; $389m) stake in Novartis, which manufactures dexamethasone and is investigating additional therapeutics. And Roche, in which Wellcome holds a £252m stake, is helping to manufacture monoclonal antibodies with Regeneron. Both Roche and Novartis report having had conversations with WHO’s ACT Accelerator about their therapeutic drugs

Wellcome also influences the pandemic response through Farrar’s position on the Scientific Advisory Group for Emergencies advising the UK government on covid-19, as well as his board seat on the Coalition for Epidemic Preparedness Innovations, a leading public- private partnership in the pandemic that has pledged more than $1bn to covid-19 vaccine development

Wellcome reports gains of £3.3bn from all investments in 2020, three times more money than the trust gave away in charity

Two investment companies on the calls with Farrar—Sequoia and Blackstone—have paid out dividends to Wellcome in recent years

https://www.bmj.com/content/372/bmj.n556

Dr Jeremy Farrar: ‘Globalist Elitist Hack’

Current SAGE Board Members/Conflicts of Interest

SAGE Member	Employment	Conflicts of Interest
Prof Alejandro Cravioto (Chair)	Universidad Nacional Autónoma de México, Puerto Vallarta, Mexico	Bill & Melinda Gates Foundation. Wellcome Trust. Chief Scientific Officer of International Vaccine Institute (IVI). Executive Director. International Centre for Diarrhoeal Disease Research (icddr, USAID, NIH. CDC. Global Fund)
Dr Hanna Nohynek (Vice-Chair)	Chief Physician, Finnish Institute for Health and Welfare (Thl), Helsinki, Finland	Bill & Melinda Gates Foundation. PATH. Oxford University on ComCov studies. Grants from EU Commission. Expert advispr to European Medicines Agency. Honoraria for GSK and Pfizer. Finnish Institute for Health and Welfare receives funding from Sanofi Pasteur. GlaxoSmithKline.
Prof Shabir Madhi	Univ of the Witwatersrand, Johannesburg, SA	Funding from Pfizer, Minervax, GlaxoSmithKline , Novavax. Bill & Melinda Gates Foundation. International Vaccine Institute (IVI) Scientific Advisory Committee. BMGF Global Health Scientific Advisory Committee. Advisor to the Pfizer Group B streptococcal (GBS) vaccine program. Member of the DSMB of GSK and Janssen. Chair of the DSMB of CAPRISA. Clinical-Regulatory Advisory Board of CureVac for Covid-19 vaccine. National Principal Investigator, AstraZeneca ChAdOx-nCoV19 vaccine. Wits Health Consortium funded by Novartis, GSK, Medimmune, Novovax. Mitsubishi. Merck (MSD), Novavax .
Prof Peter McIntyre	Dunedin School of Medicine, Univ of Otago, Dunedin, New Zealand	Member of the DSMB for the Novavax Covid-19 vaccine. Member of the New Zealand Scientific and TAG on COVID-19 vaccines. Deputy Director of Australia’s National Centre for Immunisation Research and Surveillance of Vaccine- Preventable Diseases (NCIRS). investigator on Wellcome Trust grant.

https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/members

Current SAGE Board Members/Conflicts of Interest

SAGE Member	Employment	Conflicts of Interest
Prof Anthony Scott	London School of Hygiene and Tropical Medicine. KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya	Funding from Wellcome Trust, Bill and Melinda Gates Foundation, National Institute for Health Research (NIHR). Worked with WHO and GAVI on vaccines. Joint Committee on Vaccination and Immunisation (JCVI) Board member. Director of the NIHR Health Protection Research Unit in Immunisation. Advisor to UK Health Security Agency. World Bank International Vaccines Task Force.
Prof Kathleen M. Neuzil	Director, Univ of Maryland School of Medicine, Baltimore, USA	Funding from Pfizer and NIH. Bill and Melinda Gates Foundation-funded Typhoid Vaccine Acceleration Consortium (2016-2021). CDC Advisory Committee on Immunization. Serum Institute of India, Ltd. Co-chair of the NIH COVID Vaccine Prevention Network. Univ of Maryland funding from GSK, Merck, Nosocomial Vaccine Corporation, ICON Clinical Research. Previous employment: PATH. Studied at Johns Hopkins University School of Medicine. Member on the Centersfor Disease Control and Prevention’s Advisory Committee on Immunization Practices. Associate Editor of the journal Vaccine
Prof Kim Mulholland	Professor of Child Health and Vaccinology, London School of Hygiene and Tropical Medicine. Murdoch Children's Research Institute (MCRI), Melbourne, Australia	Safety Monitoring Committee from the Novavax Covid-19 Vaccine. Novavax Maternal RSV immunization project. PCV13 vaccination project on adult pneumonia in Mongolia funded by Pfizer. Principal Investigator in pneumococcal vaccine trials 1 and 2 funded by the Bill and Melinda Gates Foundation. Member of Gates Foundation DeCoDe Committee to review CHAMPS. Receives funding from GAVI.
Prof Noni MacDonald	Paediatrics, Dalhousie University, Halifax, Canada	Funding from Bill and Melinda Gates Foundation, WHO (Consultancy). Academic Committee Member of Leger, Canada. Board member of International Vaccine Institute. Member of the SAGE Working Group on Vaccine Hesitancy

https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/members

Current SAGE Board Members/Conflicts of Interest

SAGE Member	Employment	Conflicts of Interest
Prof Rakesh Aggarwal	Director, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India	MSc from London School of Hygiene and Tropical Medicine
Dr Jaleela Jawad	Consultant, Ministry of Health Manama, Bahrain	CDC USA
Dr Sonali Kochhar	Assoc Prof, Univ of Washington, Seattle, USA	Funding from Bill & Melinda Gates Foundation, Wellcome Trust.
Prof Punnee Pitisuttithum	Mahidol University, Bangkok, Thailand	Safety Monitoring Committee for the U.S. Military HIV Research Program. Principal investigator Safety of Tri Fluvac influenza vaccine and MSD-funded 9vHPV vaccine.
Dr Folake Olayinka	Immunization Team Leader, USAID (Public Health Institute STAR Fellow). Washington, USA	Advisor to the WHO-AFRO Regional Immunization Technical Advisory Group.
Dr Ezzeddine Mohsni	Programme Essaha Aziza, European Union Tunis, Tunisia	Funding from Bill and Melinda Gates Foundation, Gavi and WHO.
Dr Ilesh V. Jani	Director General, National Institute of Health, Marracuene, Mozambique	Funding from CEPI and Bill and Melinda Gates Foundation, Janssen Vaccines & Prevention B.V., US National Institutes of Health (NIH), the HIV Vaccine Trial Network (HVTN). Grant/research support from WHO
Prof Andrew Pollard (former member)	Director of the Oxford Vaccine Group	Chief investigator for the Oxford-AstraZeneca COVID-19 vaccine clinical trials. Chair, Joint Committee on Vaccination and Immunisation (JCVI), Chair Scientific Advisory Group on Vaccines at the European Medicines Agency, National Institute for Health and Care Excellence (NICE, UK). Senior Advisor to the Medicines and Healthcare Products Regulatory Agency (MHRA) Panel, Advisor to the European Medicine Agency (EMA). Lead developer of the Bexsero meningococcal B vaccine, previously owned by Novartis and now owned by GSK. Funding from Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI),

https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/members

WHO guideline on country pharmaceutical

pricing policies

2020

Guideline Development Group Members
Member	Position	Conflicts of Interest/Funding	Conflicts of Interest/Position
YingYao Chen	Director, Key Lab of Health Technology Assessment Fudan University, China	Bristol-Myers Squibb, Medtronic, Braun, Edwards, BGI, Roche Diagnostics	Advisory Group for John Hopkins Bloomberg School of Public Health,
Andrew Hill	Senior Visiting Research Fellow Department of Pharmacology and Therapeutics, The University of Liverpool, the United Kingdom	Merck, Janssen, Bill and Melinda Gates Foundation, USAID, NIH, Wits RHI, Rainwater Charitable Foundation, Unitaid,	WHO consultant, Advisor to Bill and Melinda Gates Foundation, Advisor to Clinton Health Access Initiative, Roche employee,
Shadi Saleh	Founding Director Global Health Institute, American University of Beirut, Beirut, Lebanon	Novartis and Janssen Pharmaceuticals	Advisor to World Bank, WHO and UN on health care financing policy
Fatima Suleman	Chairperson, National Medicines Pricing Committee National Department of Health, University of KwaZulu-Natal, Durban, South Africa	World Health Organization, consulting firm HERA, and South African National Department of Health	Director: World Health Organization Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice at Univ Kwazulu-Natal, Fulbright Scholar 2002- 2004
Sabine Vogler	Head of the Pharmacoeconomic Department, Austrian National Public Health Institute, Vienna, Austria	BioMérieux, Janssen, Abbott, BioRad, Wellcome Trust, Accelerate Diagnostics S.L, BD Switzerland Sàrl	Head of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies Gesundheit Österreich GmbH

https://apps.who.int/iris/bitstream/handle/10665/335692/9789240011878-eng.pdf

ACTaccelerator ACCESS TO COVID-19 TOOLS

Co-Chair’s Update Member States COVID-19 Briefing 19 November 2020

https://apps.who.int/gb/COVID-19/pdf_files/19_11/ACT_Accelerator.pdf

Corruption: World Health Organisation under scrutiny

https://apps.who.int/iris/bitstream/handle/10665/78660/ee20.pdf;jsessionid=4FD65863A1D34D254268B87F6DFEB313?sequence=1

Corruption: World Health Organisation under scrutiny

Guidelines:

13. WHO should avoid indirect collaboration (particularly if arranged by a third party acting as an intermediary between WHO and a commercial enterprise)

https://apps.who.int/iris/bitstream/handle/10665/78660/ee20.pdf;jsessionid=4FD65863A1D34D254268B87F6DFEB313?sequence=1

Corruption: World Health Organisation under scrutiny

WHO guidelines state that it will not accept money from drug companies, but how rigorous is it in enforcing this? Michael Day investigates

In the email dated 16 June 2006, Dr Benedetto Saraceno (director of WHO’s Department of Mental Health and Substance Abuse) thanks Mary Baker of the European Parkinson's Disease Association (EPDA), “for raising the $10 000 from GlaxoSmithKline (on WHO's behalf)“requested by the WHO.” “Unfortunately,” he says, “WHO cannot receive funds from pharmaceutical industry. Our legal Office will reject the donation. Therefore, I suggest thatthis money should be given to EPDA.”

The sum was then to be passed on to WHO—ostensibly with the intention of obscuring the origins of the donation.

https://www.bmj.com/content/334/7589/338

Corruption: World Health Organisation under scrutiny

Conflict of Interest and Bias in Health Advisory Committees: A case study of the WHO’s EMF Task Group
Maisch Don JACNEM. Vol. 21. No. 1 pages 15 – 17. April 2006

The case of WHO, Michael Repacholi and the International Commission on Non-Ionizing Radiation Protection (ICNIRP)

Michael Repacholi Head of International
EMF Project, WHO

1. Michael Repacholi, head of the WHO’s International EMF Project, is also Chairman Emeritis of ICNIRP

“WHO’s Repacholi declared that Mobile Telephone Masts and the microwave radiation (the EMFs) emitted by them and other such devices not to be dangerous.” (2007)

2. “Microwave News” reported that Repacholi, as head of the EMF Project, receives $150,000 annually from the cellphone industry.

3. ICNIRP clearly states on its website that all commission members are independent Experts. ICNIRP also does not accept funding from industry. The WHO failed to declare this obvious conflict of interest

http://www.next-up.org/pdf/who_conflict.pdf

WHO: Controlling the Covid Narrative

Dr Francesco Zambon, former WHO employee

The W.H.O. press office denied Director-General Tedros was personally involved in killing the Zambon report

Emails and chat messages allegedly showed that former W.H.O. Assistant Director-General Dr. Ranieri Guerra, the organization’s liaison to Italy during the coronavirus outbreak, actually made false statements as well as working to suppress the Zambon report because it embarrassed the Italian government.

Beijing used its influence within W.H.O. to prevent the organization from criticizing China or fully investigating the origins of the pandemic in China. Zambon told AFP

WHO: Controlling the Covid Narrative

Dr Francesco Zambon, former WHO employee

14 April 2021

“The report which was a global plan for Covid Response, never saw the light, says, Zambon.

“This affair has damaged the reputation of WHO. The lack of independence, transparency. The organisation is bound by personal interests, by government interference and financial powers.” says Zambon

https://news.sky.com/story/covid-19-whistleblower-claims-who-tried-to-force-him-to-change-report-about-italys-pandemic-protocols-12274621

WHO complicity in vaccine misinformation

“We want digital actors doing more to make it known around the world that#VaccinesWork”

Statement by Dr Tedros Adhanom Ghebreyesus

WHO Director-General

https://www.who.int/news/item/04-09-2019-vaccine-misinformation-statement-by-who-director-general-on-facebook-and-instagram

WHO collusion in vaccine misinformation

https://www.who.int/news-room/feature-stories/detail/immunizing-the-public-against-misinformation

Facebook collusion in censorship

https://about.fb.com/news/2021/08/taking-action-against-vaccine-misinformation-superspreaders/

https://www.facebook.com/formedia/blog/together-against-covid-19-misinformation-a-new-campaign-in-partnership-with-the-who

WHO Programme for International Drug Monitoring

WHO's Adverse Events from Immunization Reporting System

VigiLyze

Global Signal Detection and Management tool

VigiFlow

National Vaccine Safety Surveillance

WHO Collaborating Centre for International Drug Monitoring

VigiBase

WHO's global database for Adverse Events from Immunization

WHO's Vaccine Advisory Committee

VIPS Member

Founding and Permanent member of the Gavi Board

VIPS Member

VIPS Member

Collaboration between the Gavi Secretariat, World Health Organization (WHO), Bill & Melinda Gates Foundation (BMGF), United Nations Children’s Fund (UNICEF) and PATH

Vaccine Microarray Patches

Accelerate development and future uptake of vaccine MAP products for LMIC use

VIPS Member

VIPS Member

Develop a single integrated framework to evaluate and prioritise vaccine product innovations and to drive these innovations forward

https://www.gavi.org/sites/default/files/about/market-shaping/VIPS%20Steering%20Committee%20Members_FINAL.pdf

SAGE
Strategic Advisory Group of Experts on immunization
Global policies and strategies on all vaccines, vaccine-preventable diseases and technology

WHO-IVB
WHO Immunization, Vaccinations and Biologicals Regulations
Advise D-G on Vaccine Regulations

	Global Vaccine Action Plan (GVAP)
	Decade of Vaccines (2011–2020)
		Funder

To immunize more people, from infants to seniors, with a greater range of vaccines

PSPQ-SC
The Programmatic Suitability of Prequalified Vaccines Standing Committee
Ensures continuing compliance with specifications and established standards of quality

IVIR-AC
Immunization and Vaccines Related Implementation Research Advisory Committee
Vaccine value assessments, research, effectiveness and impact studies

	IPAC
	Immunization Practices Advisory Committee
	Strengthen GVAP vaccine service delivery

EPI
Expanded Programme on Immunization
Assessment - strengths and weaknesses of Immunization programmes

ECBS
Expert Committee on Biological Standardization
Establish guidelines for manufacturing, licensing and control of vaccines, blood products and related in vitro diagnostic tests and biotechnology products

GACVS
Global Advisory Committee on Vaccine Safety
Scientific advice to WHO on vaccine safety

PDVAC
Product Development for Vaccines Advisory Committee
Recommendations infectious disease pathogens, associated vaccine and monoclonal antibody product development

Developing Countries Vaccine Manufacturers Network

Strengthen vaccine manufacturers technology transfer initiatives

WHO EMP
WHO Essential Medicines and Health Products Price
Sets international standards for the manufacturing and regulation and harmonization aligned with SDG